We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
23 result(s) found, displaying 11 to 20
-
Prescription medicine decision summaryTGA decision: VOXZOGO (vosoritide) is approved to treat achondroplasia in patients 2 years of age and older whose epiphyses are not closed.
-
Prescription medicine registrationActive ingredients: vosoritide.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Pegvaliase
-
-
Prescription medicine registrationActive ingredients: pegvaliase.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KUVAN sapropterin dihydrochloride 500 mg oral powder sachet.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KUVAN sapropterin dihydrochloride 100 mg oral powder sachet.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BRINEURA cerliponase alfa (rch) 150 mg/5 mL solution for injection vial with flushing solution vial.
-
Prescription medicine registrationActive ingredients: cerliponase alfa (rch).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VIMIZIM elosulfase alfa (rch) 1 mg/mL concentrated solution for injection vial.